RxDoctor Payments Data

Michael Haag, DPM

Podiatrist · Wilmington, DENPI 1831398015

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Smith+Nephew accounts for 66.7% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $229 and has fallen 88.2% since, to $27 in 2023. That places this record below the midpoint for podiatrist clinicians in DE, where the typical reported total is $1,099.

$273in general payments, 2019–2025

Across 10 payments — averaging $27.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$183
  • Medtronic$27
  • Abbott$19
  • Organogenesis Inc.$18
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$14
  • Kerecis Limited$13

What the payments were for

  • Food & beverage$273100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$273 in reported general payments places this provider in the 25th percentile of 37 podiatrist providers in Delaware.

See all podiatrist providers in Delaware

Medicare billing

Part B allowed, 2024
$217,454
Medicare patients
999
Services billed
4,478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ciclopirox16$446
Ketoconazole14$351
Mupirocin40$280
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$271
Methylprednisolone18$119
CiclopiroxCiclopirox Olamine13$43

Paid to pharmacies, not to this prescriber.

Other podiatrist in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →